新兴市场中的新型疫苗开发所面临的科学挑战和机遇：新兴市场中的新技术，2012 年 10 月 16 日-18 日，世界疫苗大会，里昂。
Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon.
机构信息
Clinical Research & Drug Development Specialist; PATH; New Delhi, India.
出版信息
Hum Vaccin Immunother. 2013 Apr;9(4):928-31. doi: 10.4161/hv.23514. Epub 2013 Jan 15.
Abstract
Vaccines have had a major role in enhancing the quality of life and increasing life expectancy. Despite these successes and the development of new vaccine technologies, there remain multiple infectious diseases including AIDS, malaria and tuberculosis that require effective prophylactic vaccines. New and traditional technologies have a role in the development and delivery of the new vaccine candidates. The scientific challenges, opportunities and funding models for developing vaccines for low resource settings are highlighted here.
摘要
疫苗在提高生活质量和延长预期寿命方面发挥了重要作用。尽管取得了这些成功，并开发了新的疫苗技术，但仍有多种传染病，包括艾滋病、疟疾和结核病，需要有效的预防性疫苗。新的和传统的技术在开发和提供新的疫苗候选物方面都发挥了作用。本文重点介绍了为资源匮乏环境开发疫苗所面临的科学挑战、机遇和资金模式。
相似文献
1
Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon.新兴市场中的新型疫苗开发所面临的科学挑战和机遇：新兴市场中的新技术，2012 年 10 月 16 日-18 日，世界疫苗大会，里昂。
Hum Vaccin Immunother. 2013 Apr;9(4):928-31. doi: 10.4161/hv.23514. Epub 2013 Jan 15.
2
Vaccinology capacity building in Europe for innovative platforms serving emerging markets.在欧洲为新兴市场服务的创新平台进行疫苗学能力建设。
Hum Vaccin Immunother. 2013 Apr;9(4):932-6. doi: 10.4161/hv.23163. Epub 2013 Apr 1.
3
Partnering for Vaccine Emerging Markets--Berlin, June 10-11, 2013: balancing vaccine quality, capacity, and cost-of-goods in emerging markets.新兴市场疫苗合作——2013年6月10 - 11日于柏林：平衡新兴市场中的疫苗质量、产能与生产成本
Hum Vaccin Immunother. 2013 Sep;9(9):2022-4. doi: 10.4161/hv.26235. Epub 2013 Aug 21.
4
Economics and financing of vaccines for diarrheal diseases.腹泻病疫苗的经济学与融资
Hum Vaccin Immunother. 2014;10(6):1568-81. doi: 10.4161/hv.28885. Epub 2014 Apr 22.
5
Challenges and impact of conducting vaccine trials in Asia and Africa: New Technologies in Emerging Markets, October 16th-18th 2012; World Vaccine Congress, Lyon.亚洲和非洲开展疫苗试验的挑战和影响：新兴市场的新技术，2012 年 10 月 16 日-18 日；世界疫苗大会，里昂。
Hum Vaccin Immunother. 2013 Apr;9(4):924-7. doi: 10.4161/hv.23405. Epub 2013 Jan 15.
6
Infectious disease research investments: systematic analysis of immunology and vaccine research funding in the UK.传染病研究投资：英国免疫学和疫苗研究资金的系统分析。
Vaccine. 2013 Dec 5;31(50):5930-3. doi: 10.1016/j.vaccine.2013.10.048. Epub 2013 Oct 25.
7
Vaccines for epidemic infections and the role of CEPI.针对传染病的疫苗和 CEPI 的作用。
Hum Vaccin Immunother. 2017 Dec 2;13(12):2755-2762. doi: 10.1080/21645515.2017.1306615. Epub 2017 Apr 4.
8
United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.美利坚合众国卫生与公众服务部支持在发展中国家推进流感疫苗生产。
Vaccine. 2011 Jul 1;29 Suppl 1:A48-50. doi: 10.1016/j.vaccine.2011.02.080.
9
Vaccine manufacturing: challenges and solutions.疫苗生产：挑战与解决方案。
Nat Biotechnol. 2006 Nov;24(11):1377-83. doi: 10.1038/nbt1261.
10
Quality vaccines for all people: Report on the 16th annual general meeting of the Developing Countries Vaccine Manufacturers' Network, 05-07th October 2015, Bangkok, Thailand.面向所有人的优质疫苗：发展中国家疫苗制造商网络第16届年度大会报告，2015年10月5日至7日，泰国曼谷
Vaccine. 2016 Jun 30;34(31):3562-7. doi: 10.1016/j.vaccine.2016.02.067. Epub 2016 Mar 3.
本文引用的文献
1
Transdermal immunization: biological framework and translational perspectives.经皮免疫接种：生物学框架与转化视角。
Expert Opin Drug Deliv. 2013 Feb;10(2):183-200. doi: 10.1517/17425247.2013.746660. Epub 2012 Dec 21.
2
Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccination.越南南部四种登革热血清型的传播动态及疫苗接种的潜在影响。
PLoS One. 2012;7(12):e51244. doi: 10.1371/journal.pone.0051244. Epub 2012 Dec 10.
3
Do we know the Th1/Th2/Th17 determinants of vaccine response?我们是否了解疫苗反应的 Th1/Th2/Th17 决定因素？
Expert Rev Vaccines. 2012 Nov;11(11):1307-10. doi: 10.1586/erv.12.111.
4
Controlling dengue with vaccines in Thailand.在泰国用疫苗控制登革热。
PLoS Negl Trop Dis. 2012;6(10):e1876. doi: 10.1371/journal.pntd.0001876. Epub 2012 Oct 25.
5
Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.病毒样颗粒作为一种高效的疫苗平台：多样化的目标和生产系统以及临床开发的进展。
Vaccine. 2012 Dec 17;31(1):58-83. doi: 10.1016/j.vaccine.2012.10.083. Epub 2012 Nov 6.
6
Innovative financing for health: what is truly innovative?创新的卫生筹资：什么是真正的创新？
Lancet. 2012 Dec 8;380(9858):2044-9. doi: 10.1016/S0140-6736(12)61460-3. Epub 2012 Oct 24.
7
Killed but metabolically active vaccines.已死亡但仍具有代谢活性的疫苗。
Curr Opin Biotechnol. 2012 Dec;23(6):917-23. doi: 10.1016/j.copbio.2012.04.005. Epub 2012 May 18.
8
Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.不同佐剂在肌肉注射和鼻内给药途径下对去污剂裂解A/H3N2流感疫苗诱导的小鼠体液免疫和细胞免疫反应的影响。
Clin Vaccine Immunol. 2012 Feb;19(2):209-18. doi: 10.1128/CVI.05441-11. Epub 2011 Dec 21.
9
Vaccines for the twenty-first century society.二十一世纪的疫苗。
Nat Rev Immunol. 2011 Nov 4;11(12):865-72. doi: 10.1038/nri3085.
10
Product Development Partnerships: Case studies of a new mechanism for health technology innovation.产品开发伙伴关系：卫生技术创新新机制的案例研究。
Health Res Policy Syst. 2011 Aug 26;9:33. doi: 10.1186/1478-4505-9-33.
Zotero 插件